A prospective study examining the expression of STAT 1, 3, 6 in prurigo nodularis lesions with its immunopathogenic and therapeutic implications

Author:

Agrawal Diksha1,Sardana Kabir1ORCID,Mathachan Sinu Rose1ORCID,Bhardwaj Minakshi2,Ahuja Arvind2,Jain Swasti2

Affiliation:

1. Department of Dermatology and STDs Dr RML Hospital and ABVIMS New Delhi India

2. Department of Pathology Dr. RML Hospital and ABVIMS New Delhi India

Publisher

Wiley

Subject

Dermatology

Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Abrocitinib for prurigo nodularis: Clinical efficacy and safety profile;Journal of the European Academy of Dermatology and Venereology;2024-09-12

2. Prurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics;International Journal of Molecular Sciences;2024-05-09

3. JAK1 inhibitor meets primary endpoint in prurigo nodularis;Medicom Conference Report AAD 2024;2024-04-22

4. A critical evaluation of nemolizumab for prurigo nodularis;Expert Review of Clinical Immunology;2024-01-19

5. Failure of Dupilimab With Severe Prurigo Nodularis That Responded Well to Abrocitinib;Dermatitis®;2023-12-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3